The LGALS3 inhibitor GB0139 has shown promise in acute lung injury where its mechanism of action involves reducing IL-6, TNF-α, and MIP-1α69, and thus may also prove efficacious in ovarian cancer where TNF-α plays a role in EMT initiation and maintenance. Here, LGALS3 is linked to ovarian cancer.